ALPHA COGNITION INC

Opaleye’s 2.9 M‑share purchase of Alpha Cognition at $7.92 signals growing institutional confidence and could drive the stock closer to its $10.10 52‑week high.

Alpha Cognition insider buying spurs optimism: Opaleye Management adds 152,336 shares, signaling confidence in a rebounding stock and upcoming clinical milestones.

Opaleye’s steady Alpha Cognition stake build signals confidence in a health‑tech firm poised to thrive under bundled payments, outcome‑based contracts, and AI‑driven diagnostics.

Opaleye Management’s steady, near‑market buy‑and‑hold of Alpha Cognition shares signals confidence in the mid‑cap healthcare firm’s fundamentals and product pipeline, with potential upside as earnings improve.

Alpha Cognition’s modest insider buys signal growing confidence in its AI medical‑decision tool, MediAI Insight, amid promising trial results and upcoming FDA approvals—could be a catalyst for a modest price uptick.

Opaleye’s fresh $5.99‑per‑share buybacks signal confidence in Alpha Cognition’s breakthrough neuro‑digital therapeutics, supporting R&D and a future growth‑positive outlook in cognitive‑health tech.

Opaleye Management’s new stake in Alpha Cognition signals confidence in its neuromodulation patent, drug launch prospects, and long‑term growth potential.

Alpha Cognition insider buying signals confidence amid patent filings; executives purchase 1.1M shares, hinting at future upside for neuromodulation investors.

Alpha Cognition insider buying: Mertz Phillip Joseph’s 8,437 options signal a bullish outlook amid a 12.4 % share dip, offering investors a potential rebound catalyst.

Alpha Cognition’s insider buys reveal quiet confidence in its AI‑powered cognitive tech and potential value‑based care gains, but investors should watch regulatory and product milestones for upside.